Back to Authors

Kahaleh, Bashar

https://orcid.org/0000-0003-4666-0250

A5043404558 | I12057038

Mayo Clinic

University of Toledo Medical Center

Citations 2

Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease

Rheumatology | September 29, 2022 | Volume: 62 | Issue: 5 | Pages: 1877-1886

10.1093/rheumatology/keac557 | PMID 36173318

Abstract Objectives To establish a framework by which experts define disease subsets in systemic sclerosis associated interstitial lung disease (SSc-ILD). Methods A conceptual framework for subclinical, clinical and progressive ILD was provided to 83 experts, asking them to use the framework and classify actual SSc-ILD patients. Each patient profile was designed to be classified by at least four experts in terms of severity and risk of progression at baseline; progression was based on 1-year follow-up data. A consensus was reached if ≥75% of experts agreed. Experts provided information on which items were important in determining classification. Results Forty-four experts (53%) completed the survey. Consensus was achieved on the dimensions of severity (75%, 60 of 80 profiles), risk of progression (71%, 57 of 80 profiles) and progressive ILD (60%, 24 of 40 profiles). For profiles achieving consensus, most were classified as clinical ILD (92%), low risk (54%) and stable (71%). Severity and disease progression overlapped in terms of framework items that were most influential in classifying patients (forced vital capacity, extent of lung involvement on high resolution chest CT [HRCT]); risk of progression was influenced primarily by disease duration. Conclusions Using our proposed conceptual framework, international experts were able to achieve a consensus on classifying SSc-ILD patients along the dimensions of disease severity, risk of progression and progression over time. Experts rely on similar items when classifying disease severity and progression: a combination of spirometry and gas exchange and quantitative HRCT.
Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), and the Potential Future Role of Anti-fibrotics[asterisk] in a Treatment Paradigm for SSc-ILD: A Delphi Consens

C101. NON-IDIOPATHIC INTERSTITIAL PNEUMONIA NATURAL HISTORY AND PROGNOSIS AND ILD THERAPY | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A7445-A7445

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7445